During the previous Global Liver Health Forums, HCPs have heard 17 leading international experts and discovered the latest updates in NAFLD research and current clinical practice. All sessions were live streamed with interactive Q&A!

Like to find out more?

Topics that were presented:

  • NAFLD epidemiology and co-morbidities… 
  • Disease burden and therapeutic approach…
  • The value of RWD (real world data) – MANPOWER studies
  • The NAFLD patient journey… 
  • Hepatoprotective treatment options…including the role of Essential Phospholipids (EPL)  
  • NAFLD to MAFLD - the importance of steatosis in the paradigm shift 
  • Detecting steatosis in clinical practice - EPOCH Registry 
  • Essential phospholipids - latest Real World data 
  • Digital trends in healthcare - impact on NAFLD management 
  • NAFLD profiling through physician practice - Polish RESTORE study
  • NAFLD/MAFLD guidelines overview  

Like to find out more?

Replay earlier webinars

3rd Global Liver Health Forum

    Welcome and introduction

    Sanofi
    14:00 – 14:15 (UTC+2)

    Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights

    Prof. Zobair M. Younossi
    14:15 – 14:40 (UTC+2)

    NAFLD and metabolic comorbidities. Current understanding and perspectives

    Prof. Jörn M. Schattenberg
    14:40 – 15:05 (UTC+2)

    Q&A Session
    15:05 – 15:15 (UTC+2)

    Break
    15:15 – 15:45 (UTC+2)

    Therapeutic approaches for NAFLD

    Prof. Marek Hartleb
    15:45 – 16:10 (UTC+2)

    Importance of RWE in understanding the current disease landscape: MANPOWER results put into perspective

    Prof. Chavdar Pavlov
    16:10 – 16:35 (UTC+2)

    Q&A Session 2
    16:35 – 16:45 (UTC+2)

    Conclusion and closing remarks
    16:45 – 17:00 (UTC+2)

    Welcome and introduction

    Sanofi
    10:00 – 10:15 (UTC+2)

    What does a NAFLD patient journey look like? Importance of HR-QoL

    Prof. Huiying Rao
    10:15 – 10:40 (UTC+2)

    Emerging role of hepatoprotective treatment options

    Prof. Jian-Gao Fan
    10:40 – 11:05 (UTC+2)

    Essential phospholipids. Mechanism of action in liver disease explained

    Prof. Boguslaw Okopien
    11:05 – 11:30 (UTC+2)

    Q&A Session 3
    11:30 – 11:40 (UTC+2)

    Break
    11:40 – 12:10 (UTC+2)

    The role of the essential phospholipids in NAFLD continuum

    Dr Asad Izziddin Dajani
    12:10 – 12:35 (UTC+2)

    Panel discussion (including 10 minutes for Q&A session 4)
    12:35 – 13:00 (UTC+2)

    Conclusion and closing remarks
    13:00 – 13:15 (UTC+2)

Speakers

Clinical Practice Resource

Discover a wealth of materials: scientific articles, videos and presentations.

> NAFLD Disease and Diagnosis /EPL evidence / > Information for patients / > Patient cases